Connect with us

BALAXI

Balaxi Pharmaceuticals Limited (NSE: Balaxi) Q2 & H1 FY27: Revenue Up 39%, PAT Surges 450%

Balaxi Pharmaceuticals Limited (NSE: BALAXI) reports strong Q2 & H1 FY27 results with revenue up 39% and PAT surging 450%.

priyanka verma tradealone

Published

on

Balaxi Pharmaceuticals Limited (NSE: Balaxi) Q2 & H1 FY27 Results

Balaxi Pharmaceuticals Limited (NSE: BALAXI) continues to demonstrate robust growth in its branded, IPR-driven business model, particularly in frontier markets. In the first half of FY27, the company reported a 39% increase in revenue and a staggering 450% surge in PAT compared to the same period last year.

Strong Revenue Growth

The company’s total revenue for H1 FY27 stood at ₹16,023.35 crore, up from ₹12,672.58 crore in H1 FY26. This impressive growth is driven by Balaxi’s strategic focus on expanding its product portfolio and enhancing market presence in Africa and Latin America.

Profitability Boost

Profit After Tax (PAT) for H1 FY27 was ₹244.76 crore, a significant increase from ₹49.91 crore in H1 FY26. The PAT margin also improved from 0.39% to 1.53%. Earnings Per Share (EPS) surged from ₹0.09 to ₹0.44, reflecting the company’s strong financial performance.

Strategic Expansion

Balaxi Pharmaceuticals has added 37 new product registrations in H1 FY27, bringing the total to over 1,000 registered products. The company’s manufacturing facility in Jadcherla, Telangana, is ramping up commercial production, which is expected to capture margins previously paid to contract manufacturers and open new market opportunities.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of BALAXI PHARMACEUTICALS LIMITED

BALAXI PHARMACEUTICALS LIMITED belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

BALAXI
Healthcare › Drug Manufacturers - Specialty & Generic
BREAKOUT
46
Fundamental
58
Technical
52
Overall

1W +6.74%
1M +5.68%
3M -2.33%
P/E: 52.1 Cap: Small
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

BALAXI moves sideways over three months, with neither buyers nor sellers taking control. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue contracts at -7.1% CAGR. That signals structural headwinds, not a short-term blip. The stock gains 5.7% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at -7.1% CAGR and the PEG stands at 99.00. The growth does not match the price the market asks. Furthermore, flat price action adds no technical catalyst. A lower price or faster revenue growth would improve the odds. Check Fundamentals of BALAXI PHARMACEUTICALS LIMITED.

Trending